Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License entities : Gilead sciences, inc. save search
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.16 -9.38% -10.34% 340K
|
Professional, Scientific, and T...
|
| O: 200.47%
H: 0.52%
C: -43.75%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
il-12 license program agreement
AbTherx Announces License Agreement with Gilead
Published: 2023-06-07 (Crawled : 11:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.07%
H: 0.11%
C: -0.09%
license agreement
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Published: 2023-03-20 (Crawled : 13:20) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.67%
H: 6.17%
C: 4.96%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.52%
H: 2.54%
C: 2.25%
nx-0479 license protein
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 - March 20, 2023
Published: 2023-03-20 (Crawled : 13:20) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.67%
H: 6.17%
C: 4.96%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.52%
H: 2.54%
C: 2.25%
nx-0479 license protein
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
Published: 2022-11-02 (Crawled : 17:00) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
license therapeutics payment agreement milestone
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Published: 2022-10-20 (Crawled : 14:20) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.05%
H: 0.57%
C: 0.0%
blood license agreement platform cancer
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.05%
H: 2.4%
C: 1.82%
trodelvy fda breast application license review cancer her2- her2 metastatic breast cancer
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
jyseleca treatment license ulcerative colitis
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.59%
H: 1.04%
C: 0.74%
food treatment hepatitis application drug license
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
Published: 2021-09-30 (Crawled : 23:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.38%
H: 0.5%
C: -1.91%
food drug license t-cell
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-05-17 (Crawled : 09:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.07%
H: 1.71%
C: 0.86%
china cancer license breast cancer application
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Published: 2021-04-14 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.12%
H: 1.85%
C: 0.51%
treatment fda cancer approval license
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Published: 2021-04-09 (Crawled : 01:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.31%
H: 0.66%
C: 0.45%
treatment fda fda approval cancer breast cancer approval license
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.